Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study
Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic...
Saved in:
Published in | Lipids in health and disease Vol. 9; no. 1; p. 105 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
24.09.2010
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1476-511X 1476-511X |
DOI | 10.1186/1476-511X-9-105 |
Cover
Abstract | Background
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills.
Materials and methods
In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO
®
(further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.
Results
After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children.
Conclusion
Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. |
---|---|
AbstractList | Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO.sup.[R] .sup.(further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. Abstract Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. Materials and methods In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO ® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. Results After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Conclusion Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO.sup.[R] .sup.(further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills.BACKGROUNDPolyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills.In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.MATERIALS AND METHODSIn our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented.After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children.RESULTSAfter 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children.Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended.CONCLUSIONOur results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the hormonally and immunologically active eicosanoids. Recent discoveries have shown that the long-chained omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also play an important role in the central nervous system. They are essential for normal brain functioning including attention and other neuropsychological skills. In our large observational study we monitored 810 children from 5 to 12 years of age referred for medical help and recommended for consuming polyunsaturated fatty acids (PUFA) in combination with zinc and magnesium by a physician over a period of at least 3 months. The food supplement ESPRICO® (further on referred to as the food supplement) is developed on the basis of current nutritional science and containing a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc. Study objective was to evaluate the nutritional effects of the PUFA-zinc-magnesium combination on symptoms of attention deficit, impulsivity, and hyperactivity as well as on emotional problems and sleep related parameters. Assessment was performed by internationally standardised evaluation scales, i.e. SNAP-IV and SDQ. Tolerance (adverse events) and acceptance (compliance) of the dietary therapy were documented. After 12 weeks of consumption of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc most subjects showed a considerable reduction in symptoms of attention deficit and hyperactivity/impulsivity assessed by SNAP-IV. Further, the assessment by SDQ revealed fewer emotional problems at the end of the study period compared to baseline and also sleeping disorders. Mainly problems to fall asleep, decreased during the 12 week nutritional therapy. Regarding safety, no serious adverse events occurred. A total of 16 adverse events with a possible causal relationship to the study medication were reported by 14 children (1.7%) and only 5.2% of the children discontinued the study due to acceptance problems. Continuation of consumption of the food supplement was recommended by the paediatricians for 61.1% of the children. Our results suggest a beneficial effect of a combination of omega-3 and omega-6 fatty acids as well as magnesium and zinc consumption on attentional, behavioural, and emotional problems of children and adolescents. Thus, considering the behavioural benefit in combination with the low risk due to a good safety profile, the dietary supplementation with PUFA in combination with zinc and magnesium can be recommended. |
Audience | Academic |
Author | Stauss-Grabo, Manuela Huss, Michael Völp, Andreas |
AuthorAffiliation | 2 Psy Consult Scientific Services, Fuchstanzstr. 107, 60489 Frankfurt/Main, Germany 3 Engelhard Arzneimittel GmbH & Co.KG, Herzbergstrasse 3, 61138 Niederdorfelden, Germany 1 Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz, Langenbeckstr. 1; 55131 Mainz, Germany |
AuthorAffiliation_xml | – name: 2 Psy Consult Scientific Services, Fuchstanzstr. 107, 60489 Frankfurt/Main, Germany – name: 3 Engelhard Arzneimittel GmbH & Co.KG, Herzbergstrasse 3, 61138 Niederdorfelden, Germany – name: 1 Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz, Langenbeckstr. 1; 55131 Mainz, Germany |
Author_xml | – sequence: 1 givenname: Michael surname: Huss fullname: Huss, Michael email: michael.huss@ukmainz.de organization: Department for Child and Adolescent Psychiatry, Johannes Gutenberg-University, Mainz – sequence: 2 givenname: Andreas surname: Völp fullname: Völp, Andreas organization: Psy Consult Scientific Services – sequence: 3 givenname: Manuela surname: Stauss-Grabo fullname: Stauss-Grabo, Manuela organization: Engelhard Arzneimittel GmbH & Co.KG |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20868469$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kktv1DAUhSNURB-wZocsWLAhrZ3ETrxBqioelSqxACR2lh83Mx4SO9jOSMPP4hfimWlLW1Flkej6nO9e35zj4sB5B0XxkuBTQjp2RpqWlZSQHyUvCaZPiqPbysGd78PiOMYVxhVuGXtWHFa4Y13D-FHx5-s8TQOM4JJM1jvkezT5YTO7KNMcZAKDepnSBkltTXyHRrlwEO08IukM-m2dRtYhvbSDCeBQBPhp3QKNYKyWA5JmbTWg3geUKblL7lEa6K226Wy5mSBIneza5gZT8CpPElGZ0cirCGG9myljtF_6kFBMs9k8L572cojw4vp9Unz_-OHbxefy6suny4vzq1JTXqcS-ppWXSVrwxkjrdK85pISRTrCGNe90pR2mirVAVG1Aixbw5u2qzDtTaua-qS43HONlysxBTvKsBFeWrEr-LAQMiSrBxAcKtNy08iGqgZYzxXlrMJNSynJsC3r_Z41zSqvRudFBDncg94_cXYpFn4tKk4pq7sMeHsNCP7XDDGJ0UYNwyAd-DmKlnZd3XYdz8rXD5QrP4e8xCg4riqKGdvi3uxFC5nHt673uaveIsV5VfOGE95WWXX6H1V-DIxW5yT2NtfvGV7dvebt_W7ylgV0L9DBxxigFzkHu5-cyXYQBIttrsU2uWKbXMFzjWbf2QPfDfpxB947Yla6BYR_a3jM8hcFqAyq |
CitedBy_id | crossref_primary_10_1080_19390211_2018_1481165 crossref_primary_10_1016_j_clnesp_2024_05_011 crossref_primary_10_1007_s12402_013_0107_9 crossref_primary_10_1146_annurev_nutr_012809_104635 crossref_primary_10_1007_s12519_019_00227_5 crossref_primary_10_1186_s12887_021_02631_1 crossref_primary_10_1016_j_bbi_2019_05_016 crossref_primary_10_1016_j_eujim_2022_102183 crossref_primary_10_1007_s12011_022_03517_8 crossref_primary_10_2174_1871527321666220720103923 crossref_primary_10_1007_s11920_017_0762_1 crossref_primary_10_1007_s12011_024_04098_4 crossref_primary_10_1093_nutrit_nuaa103 crossref_primary_10_2174_1871527321666220517205813 crossref_primary_10_3390_nu16183113 crossref_primary_10_3390_biomedicines9080850 crossref_primary_10_1053_j_tcam_2018_08_006 crossref_primary_10_1016_j_clnesp_2018_03_126 crossref_primary_10_3390_molecules25194440 crossref_primary_10_12968_bjnn_2014_10_1_29 crossref_primary_10_4103_ijpvm_IJPVM_546_17 crossref_primary_10_1038_s41390_024_03729_9 crossref_primary_10_1007_s40675_017_0091_2 crossref_primary_10_1080_1028415X_2021_1963064 crossref_primary_10_1111_jsr_12135 crossref_primary_10_1016_j_ejmhg_2015_05_008 crossref_primary_10_3109_15622975_2011_600292 crossref_primary_10_3390_nu13114059 crossref_primary_10_1007_s12035_018_0899_x crossref_primary_10_1016_j_pnpbp_2018_11_012 crossref_primary_10_1016_j_ejmhg_2016_04_009 crossref_primary_10_1192_bjp_bp_112_114942 crossref_primary_10_3390_nu10030344 crossref_primary_10_3390_nu14235111 crossref_primary_10_1007_s00394_021_02527_x crossref_primary_10_3390_nu16223865 crossref_primary_10_1097_YCO_0b013e32834776bd crossref_primary_10_1016_j_nut_2012_07_020 crossref_primary_10_1016_j_plefa_2015_10_004 crossref_primary_10_1089_act_2011_17403 crossref_primary_10_1038_s41598_023_49283_y crossref_primary_10_3390_children1030261 crossref_primary_10_1016_j_ajp_2019_101868 crossref_primary_10_1016_j_smrv_2017_07_004 crossref_primary_10_1891_1559_4343_14_1_41 crossref_primary_10_1016_j_plefa_2014_01_004 |
ContentType | Journal Article |
Copyright | Huss et al; licensee BioMed Central Ltd. 2010 COPYRIGHT 2010 BioMed Central Ltd. 2010 Huss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2010 Huss et al; licensee BioMed Central Ltd. 2010 Huss et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: Huss et al; licensee BioMed Central Ltd. 2010 – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: 2010 Huss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2010 Huss et al; licensee BioMed Central Ltd. 2010 Huss et al; licensee BioMed Central Ltd. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 5PM DOA |
DOI | 10.1186/1476-511X-9-105 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1476-511X |
EndPage | 105 |
ExternalDocumentID | oai_doaj_org_article_9e2d79d4a45b4e6f9b5962047551fd74 PMC2955638 2503569281 A239491972 20868469 10_1186_1476_511X_9_105 |
Genre | Clinical Trial Journal Article |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GroupedDBID | --- 0R~ 29L 2VQ 2WC 4.4 53G 5GY 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAHBH AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HH5 HMCUK HYE IAO IGS IHR INH INR IPNFZ ITC KQ8 LK8 M1P M48 M7P M~E O5R O5S OK1 OVT P2P P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP NPM PMFND 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ K9. P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM |
ID | FETCH-LOGICAL-c593t-ef35282a3d96617bc939a51b181669cfbc558c5bb8e1b3be0a7d9478205fd7b43 |
IEDL.DBID | 7X7 |
ISSN | 1476-511X |
IngestDate | Wed Aug 27 01:27:59 EDT 2025 Thu Aug 21 18:13:01 EDT 2025 Sat Sep 27 18:00:35 EDT 2025 Fri Jul 25 19:28:23 EDT 2025 Tue Jun 17 21:19:31 EDT 2025 Tue Jun 10 20:42:11 EDT 2025 Wed Feb 19 02:10:38 EST 2025 Tue Jul 01 03:47:13 EDT 2025 Thu Apr 24 22:57:29 EDT 2025 Sat Sep 06 07:33:20 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Atomoxetine Final Interview Attention Deficit Hyperactivity Disorder Attention Deficit Hyperactivity Disorder Symptom Food Supplement |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c593t-ef35282a3d96617bc939a51b181669cfbc558c5bb8e1b3be0a7d9478205fd7b43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/902250668?pq-origsite=%requestingapplication% |
PMID | 20868469 |
PQID | 902250668 |
PQPubID | 42587 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_9e2d79d4a45b4e6f9b5962047551fd74 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2955638 proquest_miscellaneous_758837889 proquest_journals_902250668 gale_infotracmisc_A239491972 gale_infotracacademiconefile_A239491972 pubmed_primary_20868469 crossref_citationtrail_10_1186_1476_511X_9_105 crossref_primary_10_1186_1476_511X_9_105 springer_journals_10_1186_1476_511X_9_105 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-09-24 |
PublicationDateYYYYMMDD | 2010-09-24 |
PublicationDate_xml | – month: 09 year: 2010 text: 2010-09-24 day: 24 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Lipids in health and disease |
PublicationTitleAbbrev | Lipids Health Dis |
PublicationTitleAlternate | Lipids Health Dis |
PublicationYear | 2010 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
SSID | ssj0020766 |
Score | 2.1611485 |
Snippet | Background
Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of... Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of the... Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and pre-stages of... Abstract Background: Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and... Abstract Background Polyunsaturated fatty acids are essential nutrients for humans. They are structural and functional components of cell membranes and... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 105 |
SubjectTerms | Adolescent Affective Symptoms Attention Attention Deficit Disorder with Hyperactivity - diet therapy Attention Deficit Disorder with Hyperactivity - physiopathology Attention Deficit Disorder with Hyperactivity - psychology Attention Deficit Hyperactivity Disorder Biomedical and Life Sciences Child Child, Preschool Children Children & youth Clinical Nutrition Cohort Studies Diet therapy Dietary Supplements - adverse effects Fatty acids Fatty Acids, Omega-3 - adverse effects Fatty Acids, Omega-3 - therapeutic use Fatty Acids, Omega-6 - adverse effects Fatty Acids, Omega-6 - therapeutic use Female Food and nutrition Health aspects Humans Hyperactivity Hyperkinesis Impulsive Behavior Life Sciences Lipidology Magnesium - adverse effects Magnesium - therapeutic use Magnesium in the body Male Medical Biochemistry Nutrition Parents - psychology Patient Compliance Sleep Wake Disorders Studies Surveys and Questionnaires Unsaturated fatty acids Zinc - administration & dosage Zinc - adverse effects Zinc - therapeutic use Zinc in the body |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLgpZHaEFzQDwkTDeJHcfHBVFVSOVEpb1ZduzQlbrZqskelp_FL2TGyYamqOLC1XYetsfjbzzjbxh7rRHD2jrUHKFxxkVWK-7yUvKAhaFQQaeRZ_vsW3F6Lr4u5OJGqi-KCevpgfuBO9Yh80p7YYV0IhS1dpQvZiYUbvW1V5EJdKZnO2NqMLXQOu_vFamCI6RYDKQ-aVkcj2Vcow6Sk_0o0vb_rZxv7E63IydvuU_jrnTyiD0c4CTM-248ZvdCs88O5g2a0qstvIEY4BlPzvfZ_bPBj37AfsVknn3gOM0MrGu4Wl9uN01LRJ-IPz3Utuu2YKulbz_Ayv5AnbjcrMA2Hn4umwqWDexugkMbAh25w6p3-4D1pIAAATEQf2eMqOQ-EFtFd3yBpm-8m0VpK2DIaNMCx1fD2o2nxPgayt573UGkwH3Czk--fP98yofsDbySOu94qIk4JrO5R4sqVa7SubYydSl5KnVVu0rKspLOlSF1uQszq7wWRN8ncV6dyJ-yvWbdhOcM0jQIr3IvSmLrc4UrvSVso53ChSBmCfu4m0NTDdTmlGHj0kQTpywMTbqhSTcay2TC3o0PXPWsHnc3_URCMTYjOu5YgEJqBiE1_xLShL0lkTKkNPDHKjvcfcDuEf2WmVOCek0Z4BJ2NGmJi72aVB_uhNIMyqY1GnGYROhYJgzGWnqQ4ueasN60Bq3CmDlAJ-xZL8FjhzI0ahGEYo2ayPakx9OaZnkRicgzTfRy-Nn3u1Xw56fuGM4X_2M4D9mDPoiDnINHbK-73oSXiA079yqqgd9-wGGI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLghZoaEFzQDwk0m4SO4kPCC2IqkIqJ1bam2XHTrvSblI2WYnlZ_ELmXGyKVtarn4kcTxjz3jG38fYK4k2rC5dGaJpHIc8LrPQJLkIHRa6NHMy8jjbZ9_S0wn_OhXTKzqg_gc2N7p2xCc1Wc6Pfv5Yf0SF_-AVPk-PI56lIRoO01DiqiLusns-WER5fHwIKcTosKc9ts8Nnba2JY_e_-8a_dcmdT2B8loU1W9OJ4_Yw96qhHEnBo_ZHVftsr1xhR71Yg2vwed5-gP0XXb_rA-n77HfntOzyx-nCYK6hMt6vl5VDeF9ohlqodRtuwZdzGzzHhb6HJfG2WoBurLwa1YVMKtgcyEcGufo5B0WXfQHtKV1CNAuBoLx9ImVoXUEWtEeX6AH7K9oEXsF9MQ2DYT4aKjNcFiMjyES32ULHgn3CZucfPn--TTsSRzCQsikDV1J-DGxTiw6VlFmCplILSITUcBSFqUphMgLYUzuIpMYN9KZlZxQ_ERpM8OTp2ynqiu3zyCKHLdZYnlOoH0mNbnVZOJIk6E-8FHAjjZzqIoe4ZyINubKezp5qmjSFU26klgmAvZ26HDZgXvc3vQTCcXQjFC5fUG9PFe9kivpYptJyzUXhru0lIa4jUY8Q7MUB8MD9oZESpE044cVur8CgcMjFC41Jp56SURwATvcaok6X2xVH2yEUm1URkk0xwRakHnAYKiljpRGV7l61Sh0Dj2BgAzYs06ChwHF6NuiLYo12ZZsb414u6aaXXg88lgSyhy-9t1GC64-6pbf-fy_AzhgD7okDQr-HbKddrlyL9D2a81Lr9N_ANp3WcM priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgLghZo2oLmgHhImG4SO4mPy4qqQionKu3NsmOHrtTNVk32sPys_kJmnGxoCj1w9SOJ4_H4G8_4G8beKsSwpvIVR2iccJFUObdpIbnHQp_lXsWBZ_vse3Z6Lr7N5bwnSaK7MLf993GRHccizziCgjlXqDHkQ_ZIotYlUZ5ls8GyQmM863l7_tFptOUEZv6_9e-tDehucOQdD2nYeE6esac9YoRpN8XP2QNf77K9aY3W8nID7yDEcIbD8V32-Kx3le-xm5Cvs4sNp58PqwquVpebdd0QlydCTAeVadsNmHLhmk-wND9R7S3WSzC1g1-LuoRFDdvL3tB4T6fqsOw8O2Ac6RhAzAtE0RmCJrnzREjRHl-gdRuuX1FmCuiT1jTA8dGwssNBMD6GEvRetxBYbl-w85OvP2anvE_QwEup0pb7irhhEpM6NJri3JYqVUbGNiZnpCorW0pZlNLawsc2tX5icqcEMfTJyuVWpC_ZTr2q_T6DOPbC5akTBRHy2cwWzhB8UTZHWReTiH3ezqEue_ZySqJxqYMVU2SaJl3TpGuFZTJiH4YOVx1xx_1Nv5BQDM2IcTsUoCDqfgFr5ROXKyeMkFb4rFKW8hZNRI6QEwcjIvaeREqTXsAPK01_vQGHRwxbeko56BUleYvY0aglrudyVH24FUrd65NGK4RaEtFhETEYaqkjhcjVfrVuNBp-ITmAitirToKHASVotyLOxJp8JNujEY9r6sVF4BpPFDHI4Ws_blfBn4-653ce_EfbQ_akC8cgN98R22mv1_41orzWvgkr_De1IU72 priority: 102 providerName: Springer Nature |
Title | Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study |
URI | https://link.springer.com/article/10.1186/1476-511X-9-105 https://www.ncbi.nlm.nih.gov/pubmed/20868469 https://www.proquest.com/docview/902250668 https://www.proquest.com/docview/758837889 https://pubmed.ncbi.nlm.nih.gov/PMC2955638 https://doaj.org/article/9e2d79d4a45b4e6f9b5962047551fd74 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAvCDY-wkblB8SHRGiTOHH8hLpq01SpEwIm9c2KY2ertCalSR_Kn8VfyJ3jZmRovKSS7Xy49p3vfOffj5C3AmzYrDCFD6Zx6LOw4L6K0tg3UGgSbkRgcbZnF8n5JZvO47nLzaldWuVOJ1pFrasc98iHAhabGNbH9Mvqp4-kURhcdQwaD8l-AIYIMjfw-a2_BS564tB8gjQZBownPtgXc1-A8ol7C5HF6_9XK_-1LN1NmbwTN7XL0dlT8sTZkXTcDvwz8sCUB-RwXIIPvdzSd9Rmdtot8wPyaOYC6Ifkt2XxbDPGcUhoVdBVdbPdlDUifILhqWmRNc2WZvlC15_oMrsCZbjYLGlWavprUeZ0UdLdEXBaG4N77XTZxntoplHzULCEKQJ32lRKXxuEqWiG1-Dz2kNZyFdBHZVNTX14NK1Utz0Mj0Ha3nVDLfbtc3J5dvpjcu472gY_j0XU-KZAxJgwizS4UgFXuYhEFgcqwBClyAuVx3Gax0qlJlCRMqOMa8EQty8uNFcsekH2yqo0rwgNAsM0jzRLEaZPJSrVGRo1QnGQADbyyOfdGMrcYZojtcaNtL5NmkgcdImDLgWUxR750N2wauE87m96gpOia4Y43LagWl9JJ9ZSmFBzoVnGYsVMUgiFbEYjxsEQhc4wj7zHKSVRW8CH5Zk79ADdQ9wtOUZmeoHUbx457rUEKc971Ue7SSmdlqllJxMeoV0t3oiJc6WpNrUEd9BSBgiPvGxncNehELxZsD6hhvfmdq_H_ZpycW0RyEOBuHLw2o87Kbj9qHv-ztf_7cARedymZWC475jsNeuNeQPWXqMGVqYHZH88nn6fwu_J6cXXb1A6SSYDu4MC1xlL4XoZjv8AQPJd0A |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEvCDYuZQP8wFUitEmcix8m1MGmjq0TQpvUN2PHzlZpTUqTCpWfxTv_jXOcC3RovO01dty4Pj4Xn-PvI-Q5Bx9WpiZ1wDX2HOalkaP8OHAMPDRhZLhrcbZHx-HwlH0aB-M18qu5C4NllY1OtIpa5wmekfc4GJsA7GP8fvbNQdIoTK42DBqyZlbQOxZhrL7XcWiW3yGCK3YOPsJyv_C8_b2TD0OnJhlwkoD7pWNSxDfxpK_B8XcjlXCfy8BVLibUeJKqJAjiJFAqNq7ylenLSHOGKHNBqiPFfBj3BllneH7SIeu7e8efv7QRXz8KwxpPyI3Dnsui0AEPZ-xwUH_Biim0jAH_2oW_DOPlos1LmVtrEPfvkju1J0sHlejdI2sm2yCbgwyi-OmSvqS2ttQe2m-Qm6M6hb9Jfloe0apmHYWC5imd5RfLRVYgxii4vpqmsiyXVCYTXbylU3kG6niymFKZafpjkiV0ktHmEjotjMHTfjqtMk5UatR9FHxxitChtpjT0QaBMsreOUTd9loYMmbQmkynoA4MTXPVHlDDMEgcPC-pRd-9T06vZU0fkE6WZ-YRoa5rmI58zWIEClShirVEt4qrCPYg63fJu2YNRVKjqiO5x4Ww0VUcClx0gYsuODwLuuR1-8KsAhS5uusuCkXbDZHA7YN8fiZqxSK48XTENZMsUMyEKVfIp9RnEWwEmAzrklcoUgL1FXxYIutrFzA9RP4SA8_njCP5XJdsr_QEPZOsNG81QilqPVeIdld2CW1b8UUs3ctMvigEBKSWtIB3ycNKgtsJeRBPg_8LLdGKbK_MeLUlm5xbDHSPI7Id_OybZhf8-agr_s7H_53AM3JreDI6EkcHx4db5HZVJILJx23SKecL8wR8z1I9rXc4JV-vW6n8Bgrjmns |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXBC2P0AI-IB4SYTeJncTH5bEqj1YcWGlvlh07baRustpkD8vP4hcy4zwghR64-pHEsWf8jWf8DSHPBWBYldvcB2gc-izME19HKfctFNo4sSJwPNunZ_HJgn1e8mUXm1P30e69S7K904AsTWUzWZu8FfE0ngQsiX2ACktfgB7hN8ktBhs1RnQtwtlgb4GJHndsPv_oNNqIHF__31r5j23pasjkFb-p247md8mdDkfSWTvx98gNWx6Qw1kJNvRqR19QF9npjswPyP5p50A_JD9dFs82YhynhFY5XVeXu21ZI8MnAE9Dc9U0O6qywtRv6EqdgzIstiuqSkN_FGVGi5L2V8BpbS2etdNV6--hyqDmoYCEKRJ3ulBK31ikqWgmF2DzuktZmK-CdqlsaurDo2mlh-NheAym7d001HHf3ieL-cfv70_8Lm2Dn3ERNb7NkTEmVJEBUypIdCYioXigA3RRiizXGedpxrVObaAjbacqMYIhbx_PTaJZ9IDslVVpHxEaBJaZJDIsRZo-HevUKAQ1QicgAWzqkbf9HMqs4zTH1BqX0tk2aSxx0iVOuhRQxj3yauiwbuk8rm_6DhfF0Ax5uF1BtTmXnVhLYUOTCMMU45rZOBcasxlNWQJAFAbDPPISl5REbQEflqnu0gMMD3m35Awz0wtM_eaR41FLkPJsVH3UL0rZaZlaCgBgHDBj6hE61GJHDJwrbbWtJZiDLmWA8MjDdgUPAwrBmgX0CTXJaG2PRjyuKYsLx0AeCuSVg9e-7qXg90dd8zsf_0fbZ2T_24e5_Prp7MsRud3Ga6Af8JjsNZutfQIwsNFPnbD_Ar5RWks |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Supplementation+of+polyunsaturated+fatty+acids%2C+magnesium+and+zinc+in+children+seeking+medical+advice+for+attention-deficit%2Fhyperactivity+problems+-+an+observational+cohort+study&rft.jtitle=Lipids+in+health+and+disease&rft.au=Huss%2C+Michael&rft.au=V%C3%B6lp%2C+Andreas&rft.au=Stauss-Grabo%2C+Manuela&rft.date=2010-09-24&rft.pub=BioMed+Central&rft.eissn=1476-511X&rft.volume=9&rft.spage=105&rft_id=info:doi/10.1186%2F1476-511X-9-105&rft.externalDocID=2503569281 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon |